Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.48 |
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | MTOR | P42345 | 6/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.48 |
| ▸ | ABL1 | P00519 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | PRKDC | P78527 | 5/20 | 0.48 |
| ▸ | HCK | P08631 | 4/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15487063 | 1.00 | SRC (0.48) | SRCEGFRMTORPIK3CDABL1 | |
| SCHEMBL19718905 | 0.89 | SRC (0.48) | SRCEGFRMTORPIK3CDABL1 | |
| SCHEMBL29720975 | 0.81 | LCK (0.51) | SRCEGFRABL1KDRLCK | |
| SCHEMBL18044545 | 0.81 | LCK (0.51) | SRCEGFRABL1KDRLCK | |
| SCHEMBL30264346 | 0.80 | EGFR (0.46) | SRCEGFRMTORPIK3CDABL1 | |
| SCHEMBL24458667 | 0.80 | LCK (0.69) | SRCEGFRMTORABL1KDR | |
| SCHEMBL20162669 | 0.79 | SRC (0.56) | SRCEGFRABL1KDRHCK | |
| SCHEMBL20162816 | 0.79 | DGAT1 (0.47) | SRCKDRLCKTEKFLT3 | |
| SCHEMBL26542146 | 0.78 | EGFR (0.57) | SRCEGFRMTORPIK3CDABL1 | |
| SCHEMBL15984342 | 0.77 | EGFR (0.53) | SRCEGFRMTORPIK3CDABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | SRC 474/4885EGFR 1/4885MTOR 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.